ArticleClinical rheumatology2026
Analysis of drug use and expenditure of conventional and biological disease-modifying anti-rheumatic drugs: a study from Northwest China.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study evaluates the impact of China's National Centralized Drug Procurement policy on DMARD accessibility, cost-effectiveness, and utilization patterns in a regional rheumatology institute in Northwest China, while examining the interplay between pricing policy and COVID-19 disruptions.
methodsData were sourced from our hospital information management system (HIS) from 2018 to 2022, encompassing prescribing records for approximately 70,000 annual outpatient rheumatology visits. DMARDs were classified into three groups: conventional synthetic DMARDs (csDMARDs), targeted synthetic DMARDs (tsDMARDs), and biological DMARDs (bDMARDs). Total revenue, defined daily doses (DDD), and defined daily dose costs (DDDc) were calculated, and compound annual growth rates (CAGR) were analyzed.
resultsThe CAGR of total revenue of DMARDs from 2018 to 2022 was 0.91%. Among csDMARDs, methotrexate for injection saw the largest revenue increase (CAGR of 92.26%). Recombinant human type II tumor necrosis factor receptor-antibody fusion proteins consistently led among tsDMARDs and bDMARDs. In contrast, infliximab experienced the largest decline (CAGR of - 23.49%). Leflunomide remained the most frequently used csDMARD, while several tsDMARDs and bDMARDs, except infliximab, showed upward trends, with baricitinib, tofacitinib, golimumab, and secukinumab exceeding 200% CAGR.
conclusionsNational centralized procurement policy achieved dramatic cost reductions (e.g., tofacitinib DDDc decreased by 93.3%), directly driving increased utilization of tsDMARDs and bDMARDs. This study provides empirical evidence that aggressive pharmaceutical pricing policies can rapidly improve access to advanced rheumatologic therapies in resource-limited settings, offering a replicable model for healthcare systems worldwide. Key Points • Overall disease-modifying antirheumatic drugs (DMARDs) use showed modest growth from 2018 to 2022. • tsDMARDs and bDMARDs exhibited rapid increases in use and revenue. • Methotrexate and leflunomide remained key csDMARDs in clinical practice.
Indexed as
Identifiers
42268488What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.